- Home
- ANL vs ALGS Comparison
ANL vs ALGS Comparison
Compare ANL & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | ALGS |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | Cayman Islands | United States |
| Employees | 123 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0M | 62.2M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ANL | ALGS |
|---|---|---|
| Price | $1.85 | $7.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $46.67 |
| AVG Volume (30 Days) | ★ 1.3M | 63.2K |
| Earning Date | 02-24-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.88 | $3.76 |
| 52 Week High | $2.75 | $34.37 |
Technical Indicators
Market Signals| Indicator | ANL | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 64.46 | 39.90 |
| Support Level | $1.48 | $8.39 |
| Resistance Level | $1.71 | $9.39 |
| Average True Range (ATR) | 0.21 | 0.85 |
| MACD | 0.03 | -0.17 |
| Stochastic Oscillator | 80.95 | 1.61 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.